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ABSTRACT:
The Global Cancer Genomics Consortium (GCGC) colleagues continue to function
together as an interactive multidisciplinary team of cancer biologists and oncologists
with interests in genomics and building a bidirectional bridge between cancer clinics
and laboratories while taking advantage of shared resources among its member
scientists. The GCGC includes member scientists from six institutions in Lisbon,
United Kingdom, Japan, India and United States, and was formed in December 2010
for a period of five years. Driven by valuable lessons learned from the previous
symposiums, the fourth GCGC Symposium focused on a cross section of genomic
and epigenetic cancer medicine and it’s for this reason we chose the conference
theme - New Era of Molecular Medicine and Epigenetic Cancer Medicine: Cross
Section of Genomics and Epigenetics. This year’s symposium was co-organized by
the Organization for Oncology and Translational Research (OOTR) at the Shiran Hall,
Kyoto University, Kyoto, Japan, from November 14 and 15, 2014. The symposium
attracted around 80 participants from 14 countries, and counted with 23 invited
platform speakers. Scientific sessions included eight platform sessions and one poster
session, and three plenary lectures. The symposium focused on cancer stem cells
and self-renewal, cancer transcriptome, tumor heterogeneity, tumor biology, breast
cancer genomics, targeted therapeutics and personalized medicine. The issues of
cancer stem cells and tumor heterogeneity were echoed in most of the scientific
presentations. The meeting concluded with an oral presentation by the best poster
awardee and closing remarks by meeting co-chairs.
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INTRODUCTION

for Research, Planning, and Hospital Administration
at the Kyoto University. Prof. Minato inaugurated the
meeting by highlighting the contribution of genome
research in cancer biology and treatment and the role
played by the Kyoto University in the previous consortium
meetings. He stressed the need to developing efficient
collaborative programs to understand the molecular and
genomic details of human cancer and to develop targeted
cancer therapeutic. Scientific sessions included eight
platform sessions and one poster session, and included
three plenary lectures. The symposium focused on the
following scientific themes: 1) cancer stem cells and selfrenewal; 2) cancer transcriptome; 3) tumor heterogeneity;
4) tumor biology; 5) breast cancer genomics; 6) targeted
therapeutics; and 7) personalized medicine. The issues
of cancer stem cells and tumor heterogeneity are echoed
in most of the scientific presentations. The meeting
concluded with an oral presentation by the best poster
awardee and closing remarks by meeting co-chairs - Dr.
Masakazu Toi and Dr. Rakesh Kumar.

The Global Cancer Genomics Consortium
(GCGC) colleagues continue to function together as an
interactive multidisciplinary team of cancer biologists
and oncologists with interests in cancer genomics and
building a bidirectional bridge between cancer clinics and
laboratories while taking advantage of shared resources
among its member scientists. The GCGC includes
member scientists from six institutions in Lisbon, United
Kingdom, Japan, India and United States, and was formed
in December 2010 for a period of five years. Since the
last successful Symposium in Lisbon, Portugal in 2013,
the GCGC colleagues continue to function together
as an interactive multidisciplinary team of cancer
biologists and oncologists with interests in genomics and
building a bidirectional bridge between cancer clinics
and laboratories while taking an advantage of shared
resources among its founding members. This collaborative
network continues to enable cancer students and scholars
in academics and research and helped to nurture a crossdisciplinary collaborative approach among consortium
members and meeting participants over the years.
Motivated by valuable lessons learned from the
previous symposiums, the fourth GCGC Symposium
focused on a cross section of genomic and epigenetic
cancer medicine. And it’s for this reason we chose the
conference theme - New Era of Molecular Medicine and
Epigenetic Cancer Medicine: Cross Section of Genomics
and Epigenetics. This year’s symposium was co-organized
by the Organization for Oncology and Translational
Research (OOTR) at the Shiran Hall, Kyoto University,
Kyoto, Japan, from November 14 and 15, 2014. The
symposium attracted around 80 participants from 14
countries, and counted with 23 invited platform speakers
and a rich poster session.
Similar to previous years, the mission of the
symposium was to provide practical knowledge on
structural and cancer genomics approaches, to meet and
share experiences of the like-minded cancer experts
and leaders, to provide an exclusive platform for
focused cancer genomics endeavors, and to evaluate the
latest research developments in cancer genomics and
epigenetics.

Cancer Stem Cells and Self-renewal
The theme was introduced by the opening
conference lecture by Dr. Akihiko Yokoyama from the
Laboratory of Malignancy Control Research, Kyoto
University School of Medicine. Dr. Yokoyama presented
new molecular insights by which Mixed-lineage
leukemia fusion (MLL) oncogenes aberrantly regulate
the expression of hematopoietic stem genes, leading to
leukemia [1, 2]. Dr. Yokoyama provided experimental
evidence to suggest that MLL fusion proteins recognize
its target genes through specific bindings of the PWWP
domain of LEDGF and the CXXC domain of MLL that
specifically bind to H3K36me2/3 and non-methylated
CpGs, respectively. Because H3K36me2/3 marks are
generally linked to gene activation, this suggested that
previously transcribed genes with non-methylated CpGs
in its promoters are likely to be stimulated by MLL fusion
proteins. Dr. Yokoyama suggested that in general, MLL
fusion oncogenes function as a facilitator of self-renewal
simply by continuously activating previously-active
hematopoietic stem cell program genes to transform
hematopoietic progenitors into cancer cells.
Dr. Hiroshi Seno from the Department of
Gastroenterology and Hepatology, Kyoto University
Graduate School of Medicine highlighted the role of tumor
stem cells in digestive tumors and presented data outlining
the benefits of using lineage tracing approach in murine
models in identifying tumor stem cells (TSCs) from
resembling normal stem cells (NSCs) in the background
of self-renewal and continuous supply of progeny tumor
cells. Specifically, he utilized Dclk1creERT2/+ knock-in
mice to understand the role of doublecortin-like kinase
1 (Dclk1) in the intestinal tumors. Dr. Seno’s group

Focus on the Molecular Medicine and Epigenetic
Cancer Medicine
The fourth GCGC meeting was at the interface of
molecular cancer medicine, epigenetics and tumor biology
with a particular focus on biologic questions within
recognizable clinical framework with a forward looking
approach. The event was opened by Dr. Masakazu Toi
with a brief history of GCGC. Dr. Toi introduced the chief
guest Prof. Nagahiro Minato, Executive Vice-President
www.impactjournals.com/Genes&Cancer
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Cancer Transcriptome

found that Dclk1 does not mark intestinal NSCs and that
targeting Dclk1-marked TSCs marked could be used an
antitumor therapy without any significant damages to the
normal intestines in murine models. Dr. Seno suggested
that Dclk1 might be a unique marker to discriminate tumor
stem cells from normal stem cells in the mouse intestine.
Dr. Nobu Oshima from the Department of
Reprogramming Science, Center for iPS Cell Research
and Application at Kyoto University shared exciting data
showing the ability of OCT3/4, SOX2 and KLF4 to induce
cancer stem cell with self-renewing characteristics in
colon cancer cells. He also presented a new methodology
to collect the induced CSCs based on the dye-efflux
activity enhancement. Dr. Oshima judged the functionality
of induced CSC by its ability to differentiate in vivo and
form tumors which remarkably mimicked actual human
colon cancer tissues in terms of their pathological findings
- intratumor heterogeneity and glandular-like structure. Dr.
Oshima hopes that these methods will contribute towards
the development of better therapeutic approaches targeting
CSCs.
Dr. Yoshiteru Murofushi from the Laboratory
of Malignancy Control Research, Medical Innovation
Center at Kyoto University Graduate School of Medicine,
presented a new disease model of pheochromocytoma
using VHL patient-derived iPS cells. Von Hippel-Lindau
(VHL) disease is an autosomal dominant inherited,
family tumor syndrome caused by a germ line mutation
in the VHL tumor suppressor gene. The major problem
of research for VHL disease is the lack of disease model
that successfully recapitulate human disease phenotypes
in vitro and in vivo. To establish novel experimental
model, Dr. Murofushi’s laboratory has used VHL patientderived human iPS cells (VHL iPS) to differentiate
in culture. Although the remaining wild type VHL
should be disrupted to recapitulate the development of
pheochromocytomas, VHL iPS cells might be useful for
establishing new disease model of VHL disease, especially
for pheochromocytomas.
Dr. Takayuki Kawai from the Division of
Hepatobiliary, Pancreas and Transplant Surgery, Kyoto
University Hospital presented data showing that Keratin
19-positive cells possess cancer stem cell properties in
human hepatocellular carcinoma. Dr. Kawai’s work
demonstrated that FACS-isolated single K19+ cells
are able to self-renew, proliferate, exhibit resistance to
5-fluorouracil, express EMT related genes and form
tumors in xenograft models and many of these activities
are blocked by transforming growth factor beta receptor 1
inhibitor. Interestingly, K19+ HCC patients exhibit larger
tumors and shorter recurrence-free survival.

www.impactjournals.com/Genes&Cancer

Dr. Amit Dutt from The Advanced Centre for
Treatment, Research and Education in Cancer (ACTEC)
shared emerging data about the status of Notch pathway in
an Indian cohort of tongue squamous cell carcinoma, a sub
type of head and neck cancer. The group performed DNA
copy number and gene expression profiling of NOTCH
signaling pathway genes comprising of ligands, receptors
and target genes using quantitative real-time PCR followed
by immuno-histochemical analysis of activated NOTCH.
In addition to the tumor suppressor function of the Notch
pathway, the data presented underlined high copy number
and overexpression of NOTCH signaling pathway
components, consistent with an independent TSCC cohort
from the TCGA study. Dr. Dutt presented data examining
the influence of NOTCH1 knockdown on the treatment
of HNSCC cells with gamma secretase inhibitor XXI to
achieve an effective inhibition of the growth, survival and
migration of cells derived from patients of Indian origin.
Dr. Wonshik Han from the Seoul National
University College of Medicine Korea used the targeted
kinome sequencing on NGS platform to generate a
comprehensive profiling of the most frequently altered
genes and mutations in triple-negative breast cancer
tissues with matched normal tissues or peripheral blood
samples.
Dr. Nuno Barbosa-Morais from the Institute of
Molecular Medicine highlighted the importance of
alternative splicing (AS) in cancer and the opportunity
provided by next-generation sequencing to profile AS
in tumor samples, having shared preliminary results
of analyses on RNA-Seq data for clear cell renal cell
carcinomas and matched normal samples from The
Cancer Genome Atlas project. It was observed that AS
patterns primarily separate normal from tumor samples.
Some of the measured normal/tumor isoform “switches”
are markers of epithelial-mesenchymal transition
(EMT). Survival analysis revealed several AS events,
some reassuringly known to be associated with cancer
progression, as candidate markers for prognosis, both in
normal and tumor samples. Gene set enrichment analyses
revealed differential expression of genes associated with
oncogenic processes, namely EMT, between survival strata
defined based on candidate AS events. Dr. Barbosa-Morais
presentations illustrate the potential of AS signatures
derived from tumor transcriptome in providing etiological
leads for cancer progression and as a clinical tool.
Dr. Reshmi G from the Rajiv Gandhi Centre
for Biotechnology, India, presented the utility of
computational modeling approach to understand the
impact of viral oncoproteins upon microRNA clusters in
cancer. The goal of these integrated in-silico genomic
studies to identify microRNA and transcription factormediated regulatory networks as early detection or

3
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prognostic markers in HPV induced cervical cancer.
The group systematically explored feed-forward loops
consisting of miRNAs and transcription factors and
applied additive and weighted modelling to combine
possible transcription factor-miRNA target predictions
to identify the regulation change at a specific gene
set, pathway, or interacting network. The approach
successfully identified novel, candidate miRNA-TF
networks, for further experimental design.
Dr. Raja Mazumdar from the George Washington
University presented exciting way to conduct pan-cancer
analyses because cancer mutation and expression data
is distributed in multiple databases. We have integrated
cancer related mutation and expression data from multiple
databases and publications to create two comprehensive
mutation and expression databases called BioMuta and
BioExpress. The group then used these databases to
identify driver mutations present in multiple cancers and
identified 62 mutations in 13 genes affecting functional
sites such as DNA and ATP binding and also various
post-translational modifications (PTM) sites. Key driver
mutations identified includes p53 acetylation and zinc
binding sites, CTNNB1 phosphorylation sites and SF3B1
ubiquitylation site. Initial expression data analysis show
that genes which are highly mutated in cancer usually
do not show differential expression in tumors compared
to adjacent normal tissue. It is hoped that the approach
undertaken by Dr. Muzumdar’s lab will facilitate
identification of priority diagnostic and therapeutic targets.

high degrees of temporal/spatial heterogeneity generated
during tumor expansion and relapse, which should be
shaped by complex, but ordered processes of multiple
clonal selections/evolutions.
Dr. Radhakrishna Pillai from the Rajiv Gandhi
Center for Biotechnology presented recent findings
showing that a small fraction of drug-resistant cells,
named “persister cells,” may contribute to the tumor
recurrence via contributing to tumor heterogeneity. Using
experimental models, Dr. Pillai shared data demonstrating
that persister cells remain quiescence and rarely enter into
the cell cycle. However, such cells exhibit tumor stem
cells characteristics and eventually lead to cell population
with increased heterogeneity with respect to cell growth,
invasion, response to drugs and tumor initiation potential.
The team has further subjected diverse cell populations
to RNA sequencing to understand both the passive and
driving pathways that might be involved in drug-escape
and re- emergence. The team used stable cancer cells
expressing redox sensor and presented data showing that
the emergence of drug resistant cells was accompanied
by chronic autophagy followed by Parkin-dependant
mitophagy and increased heterogeneous cell populations.
Dr. Pillai suggested that such persister cells are likely to
counteract the beneficial effects of chemotherapy and
radiotherapy and present development of approaches to
prevent emergence of drug-resistance cell populations.
Dr. Rakesh Kumar from GW Washington University
presented a plenary lecture highlighting the lessons
from RNA-sequencing of breast cancer sub-types in
identifying the hub networks and potential new regulatory
molecules. This approach re-emphasized the notion of
genomic heterogeneity which, at-least, in-part, might be
arising from differential splicing and promoter switching
[3]. These earlier studies allowed the team to recognize
the limitations of such an approach as most breast
cancer sub-types are clonal in origin. To experimentally
address the issue of genomic heterogeneity, Dr. Kumar
laboratory decided to define the HER2 transcriptome as
an example by generating isogenic MDA-MB-231 and
MDA-MB-468 breast cancer cells stably overexpressing
HER2. To start revealing the nature of HER2-regulated
genes globelly, the team subjected such isogenic clones
to microarray and RNA-sequencing approaches. Results
from the microarray study identified HER2-influenced
genomic elements shared among two cell lines, some of
which also overlapped with that of patient microarray
datasets [4]. In addition, Dr. Kumar presented scientific
highlights pertaining to global transcriptomic changes and
differential splicing of HER2-overexpressing isogenic
clones as revealed by RNA-sequencing – a project
completed in July 2014 but yet to be summarized in
a manuscript by Ms. Prakriti Mudvari as a part of her
dissesration research work with Dr. Kumar [5]. Following
the leads from mRNA-validation studies by Ms. Mudvari,
Dr. Kumar also presented preliminary data about the

Tumor Heterogeneity
Dr. Seishi Ogawa, Professor of Pathology and
Tumor Biology at the Graduate School of Medicine Kyoto
University presented a plenary lecture on mutational
landscape and clonal architecture in low-grade gliomas.
Dr. Ogawa shared his experience with the pathogenesis of
lower grade glioma which if not treated early on leads to
devastating high grade gliomas. Despite recent findings
of frequent mutations in IDH1 and other genes, our
knowledge about the pathogenesis of lower grade is still
incomplete. By combining high-throughput sequencing
data of 760 cases from two large cohorts with extensive
validation sequencing, the team delineated the entire
picture of genetic alterations and affected pathways
in Lower grade gliomas with sensitive detection of
novel drivers. Lower grade gliomas are classified into
three distinct subtypes characterized by discrete sets
of mutations and distinct clinical behaviors. Mutations
showed significant positive/negative correlations and
chronological hierarchy as inferred from different
allelic burdens among coexisting mutations, suggesting
functional interplays between mutations that drive clonal
selection. Based on an extensive serial/multi-regional
sampling analyses, Dr. Ogawa’s work further revealed

www.impactjournals.com/Genes&Cancer
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expression of two newly identified HER2-regulated
proteins: ABCC3 with an established role in therapeutic
resistance and a splicing factor with role in transformation.
Interestingly, HER2-regulated ABCC3 protein with a
putative role in therapeutic resistance was found to exist
as multiple isoforms, raising the possibility of protein
isoform-specific functions in therapeutic resistance.
Further, these newly identified HER2-regulated molecules
are highly overexpressed as well as co-overexpressed with
HER2 in breast cancer and cancer, at-large, in genomic
databases. Dr. Kumar’s also discussed another HER2centered collaborative study involving HER2 ChIPsequencing to determine the genomic effects of the nuclear
HER2 in stimulated breast cancer cells and how this will
help to broaden the HER2 transcriptome. He closed his
presentation with a working model to understand the
molecular basis of co-overexpression and upregulation
of these newly recognized HER2-target proteins with
functions in drug-sensitivity and transformation, and
perhaps, in HER2-biology at-large.

binding domain, and lung metastases of colorectal cancer
[7]. For the first time, Dr. Costa’s work showed that high
MTDH expression is an independent factor for lungrelapse and survival and could be a potential biomarker
for lung relapse in colon cancer. Finally, Prof. Costa
stressed the need to expend the lessons of organ-specific
colonization from bone metastases to other common sites
of metastases, and provided a peek into very interesting
set of experiments in his laboratory wherein the team
is undertaking steps to capture the dynamic of gene
expression during consecutive episodes of metastases in
the same patient.
Dr. Dominique Scherer from the German Cancer
Research Center, Heidelberg shared her vision of
pharmacogenetics in colorectal cancer prevention using
non-steroidal anti-inflammatory drugs (NSAIDs) which
inhibit prostaglandin synthesis by targeting COXenzymes. Although recent meta-analyses showed the effect
of NSAIDs on primary cancer prevention, metastasis
prevention and patient survival, the risk of gastrointestinal
toxicity among NSAID remains high. Dr. Scherer
presented data showing that genetic variation in specific
alleles in distinct genes including PTGS1, PTGS2, PGDH
and UGT modifies the beneficial effects of NSAIDs in
colorectal cancer and may be also important in colorectal
cancer predisposition. Her data showed that genetic
variants in PGES, CRP, SRC and GPX3 were associated
with increased risk of cardiac symptoms/toxicity among
NSAID users. Therefore, it is crucial to identify genetic
variants that interact with NSAIDs in colorectal cancer
prevention and drug-related toxicities to establish targeted
chemoprevention strategies.
Dr. Norman Lee from the George Washington
University presented data about potential molecular basis
of population disparities of prostate cancer risk with a
particular focus on differential methylation patterns,
expression of splicing factor and variants. The team
found population-based differential alternative splicing
of several key oncogenes in specimens from of African
American (AA) with non-AA patients and generated
variants tend to exert a strong oncogenic phenotype.
Further, this phenomenon correlated well with race
associated methylation patterns and expression of splicing
factors. Prof. Lee hypothesize that certain splice variants
specific to AA population encode gene products with a
stronger oncogenic activity and thus, could explain, inpart, the noted risk of prostate cancer in certain population.

Tumor Biology
Dr. Makoto Noda from the Laboratory for
Malignancy Control Research at Kyoto University
Graduate School of Medicine presented a plenary lecture
on RECK: a tumor suppressor downregulated by multiple
oncogenic pathways. Dr. Noda discussed the biology of
RECK tumor suppressor which encodes a membraneanchored glycoprotein with an ability to regulate matrix
metalloproteinases. Accordingly, viable Reck–deficient
mice was found to be prone to spontaneous tumorigenesis
while forced RECK expression leads to inhibition of
angiogenesis, invasion, and metastasis in model systems.
Clinically, RECK downregulation in cancer correlates
well with a poor prognosis. Dr. Noda believes that RECK
provides a unique opportunity to reactivate the dormant
RECK in cancer cells with a goal to suppress malignant
phenotypes.
Dr. Luis Costa from the Institute of Molecular
Medicine and Medical Faculty of Lisbon University
highlighted the significance of molecular understanding
of distinct biologic steps until the formation of clinical
detectable metastases in selecting cancer patients at
higher risk for metastases, and also debated if bone
metastasis is a useful paradigm to follow for developing
effective therapeutics. Dr. Costa presented data showing
overexpression of Bone Metastases (BM) genes in tumor
cells residing in BMs - independent of primary tumor
type - and provided support to the cooperative function
among IL11/CTGF, IL11/ADAMTS1, CTGF/CXCR4,
CTGF/ADAMTS1, and MMP-1/ADAMTS1, in the bone
microenvironment [6]. Dr. Costa’s team shared data about
the correlation between the amplification and expression
of Metadherin (MTDH) which contains a lung vasculature-

www.impactjournals.com/Genes&Cancer

Breast Cancer Genomics
Dr. Hisataka Sabe from the Department of
Molecular Biology, Hokkaido University Graduate School
of Medicine discussed the significance of mesenchymal
machinery in metastasis in different cancer sub-types with
a particular focus on the small GTPase Arf6 signaling
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Targeted Cancer Therapeutics

pathway. Dr. Sabe presented data showing that Arf6
interacts with AMAP1 which in-turn, binds to EPB41L5
– a component of mesenchyme – and hence, contributes
to mesenchymal properties that might be cancer-type
specific. Because AMAP1-EPB41L5 interactions regulate
E-cadherin and β1 integrin signaling, Arf6 is believed
to play a mechanistic role in epithelial-mesenchymal
transition. Dr. Sabe also presented data showing the
activation of Arf6 by two distinct mechanisms – by the
cell surface tyrosine kinases in breast cancer and by
G-protein coupled receptors (GPCRs) in clear cell renal
cell carcinomas. Therefore, Arf6 activation - independent
of its upstream mode of stimulation- cooperates with the
Arf6-AMAP1-EPB41L5 pathway to promote EMT. Dr.
Sabe closed his presentation by highlighting the roles
of genome in eliciting the Arf6-driven EMT pathway in
metastasis of human cancer.
Dr. Sudeep Gupta from the Tata Medical Center
discussed a recently conducted randomized study wherein
a single depot injection of progesterone prior to surgery in
patients with node positive breast cancer exhibited clinical
benefits [8]. Dr. Gupta shared results from on-going studies
designed to understand the potential mechanisms behind
the noted effects of progesterone. Using cell-based model
systems, the team performed genome wide expression
analysis and identified serum and glucocorticoid regulated
kinase SGK1 as a progesterone up-regulated transcript.
In addition, progesterone also down regulated two
microRNAs that target the 3’UTR region of SGK1. Dr.
Gupta proposed a novel dual-regulatory model wherein
progesterone up-regulates SGK1 as well as downregulates the expression of microRNAs which in-turn,
targets SGK1. He also suggested that progesterone could
downregulate the expression of its own receptor through
upregulation of a microRNA.
Dr. Louis Chow from Organisation for Oncology
and Translational Research and UNIMED Medical
Institute presented a comprehensive comparative summary
of available diagnostic gene signatures and assays for
breast cancer prognostic and/or predictive assessment.
Dr. Chow highlighted the benefits of including the
proliferation or estrogen receptor (ER) pathway in
assay platforms for prognosis. For example, the 21-gene
Oncotype DX assay is a prognostic and predictive test
that uses ER, proliferation, HER2 genes, amongst others
to normalize for RNA quantity, and the expression levels
are used to calculate a recurrence score for ER positive,
node negative breast cancer. In contrast, Endopredict uses
12-genes not involving ER, PR or HER2 status to classify
the prognosis of HER2 negative breast cancer. The gene
signatures also predict the risk of recurrence for patients
- high probability of metastasis, free survival, or high risk
for distant metastasis.

www.impactjournals.com/Genes&Cancer

Dr. Stefan Knapp from the University of Oxford
presented an update on recent development of chemical
probes for epigenetic reader domains of the bromodomain
family. Bromodomains (BRDs) are evolutionary
conserved protein interaction modules that specifically
recognize ε-N-lysine acetylation motifs, a key event in the
reading process of epigenetic marks. The human proteome
encodes 61 of these highly diverse domains present
in 41 mainly nuclear proteins. Recently, Dr. Knapp’s
research group has developed a platform for screening
and designing of specific bromodomain inhibitors based
on a large number of crystal structures and biochemical/
cell based assays [9]. The probe project at the SGC
(www.sgc.ox.ac.uk) resulted in the development of a
comprehensive set of chemical probes covering most the
human bromodomain family. The development of these
research tools led to new validation of new targets and
the initiation of first set of clinical studies in cancer [10,
11]. As an example of the translational aspects of this
effort, Dr. Knapp reported on the development of dual
kinase/bromodomain inhibitors [12] and specific chemical
probes targeting the bromodomains of CBP/P300 [13] and
BRPF1B [unpublished].
Dr. Junko Murai from the Medical Innovation
Center at the Kyoto University Graduate School of
Medicine presented new research revealing a novel
mechanism of action for poly(ADP-ribose) polymerase
(PARP) inhibitors – the most promising anti-cancer
agents. The mechanism of anticancer effect of PARP
inhibitors has been interpreted by single strand break
(SSB) repair inhibition through catalytic PARP inhibition.
Her team discovered that inhibitors promote trapping of
PARPs at the damaged DNA site and that trapped PARPDNA complexes are more cytotoxic than unrepaired
single-stranded breaks [14]. Dr. Murai also found that the
potency of PARP-trapping is markedly (more than 1,000
folds) different among five clinical PARP inhibitors inspite of an equivalent high catalytic PARP inhibition [15].
Dr. Murai stressed the need to start considering the PARPtrapping efficacy as an addition variable for clinical utility
of a given PARP inhibitor.

Personalized Medicine
Dr. Stephen Fox from Peter MacCallum Cancer
Centre in Melbourne shared his vision of “Cancer 2015
- a model for personalized medicine” program. Cancer
2015 study is a large-scale, prospective, multi-site
cohort of newly diagnosed cancer patients from Victoria,
Australia with 1718 patients recruited, 854 patients of
which have been currently sequenced for 48 cancer genes.
Clinically relevant mutations were identified in 63%
6
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of patients, with 26% of patients displaying a mutation
with therapeutic implications. While the prevalence
of mutations was consistent with other institutionally
based series for some tumor types (breast carcinoma
and colorectal adenocarcinoma), others were different
(lung adenocarcinoma and head and neck squamous cell
carcinoma) which has significant implications for health
economic modelling of particular targeted agents. Further,
in some tumour types new areas of research were identified
through recognition of novel genotypes. Reliable delivery
of a diagnostic assay to screen for a range of actionable
mutations was achieved, providing evidence for a reclassification of some cancers and opening unexpected
avenues for investigation and treatment of cancer patients.
Dr. Fox also presented his vision about the planned
utilization of the Cancer 2015 study for modeling health
economics of particular targeted agents.
Dr. Fumihiko Matsuda from the Center for Genomic
Medicine at Kyoto University Graduate School of
Medicine presented the utility of a large-scale genome for
comprehensive human biology. As a model of “Human
Biology”, the team initiated “The Nagahama Cohort
Study” - a community-based prospective genome cohort
study in Nagahama City. The baseline survey started in
2007, and the enrollment of 10,082 healthy residents
was completed in 2010. In addition to the collection of
health-related information and the measurement of 115
biochemical and hematological traits, the team conducted
an integrated comics study. A genome scan using SNP
arrays was initiated in 2009, and approximately 4,000
DNA samples have been analyzed to date. Dr. Matsuda
presented interim analysis of overall data and discuss the
results of the cross-sectional analysis.

broad activities that might be feasible within the current
framework of consortium members and the precise nature
of such collaborative theme is likely to be evolved soon.

CONCLUSIONS
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The symposium achieved one of the core GCGC
goals to bring together its founding members from
six institutions as well as a large number of interested
scientists and potential collaborators to share their exciting
research findings. Looking at the trend during the past
meetings, it was obvious that certain research themes such
as tumor heterogeneity and transcriptome have evolved
over the years. It remains unclear whether we are able to
harvest the fruits of whole genome sequencing completed
so far. In general, each session provided a spectrum of
findings ranging from an overview to specific research
questions that might be acting as a bottleneck to move
the field forward. As always the case in science and
medicine, many of the presentations raised more exciting
questions for investigation while addressing a well-defined
research problem. The organizing committee as well as
some of meeting participants observed the need to include
additional shared activities some of which might require
financial resources. The group identified a short list of
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